Effects of Newer Veterinary Macrolide Antimicrobials on the CYP3A-Dependent Metabolism in Cattle Liver Microsomes: Potential Metabolic Drug-Drug Interaction with Monensin.

Traditional macrolide antimicrobials are inhibitors of cytochrome P4503A (CYP3A) in cattle liver. Monensin (MON), an ionophore with a narrow safety margin, undergoes CYP3A-dependent O-demethylation, and its incompatibility with macrolides is well recognized in livestock animals. This study evaluated the effects of newer macrolides-tilmicosin (TIL), tulathromycin (TUL), and gamithromycin (GAM)-on CYP3A-dependent metabolism in bovine liver microsomes and examined how these drugs influence MON hepatic metabolism. Molecular docking studies were also performed to predict their interactions with CYP3A enzymes. The CYP3A-dependent enzyme activity, testosterone 6β-hydroxylase, was inhibited in the presence of triacetyl-oleandomycin (used as a reference macrolide), as well as with MON. None of the other macrolides tested affected this enzymatic activity. All macrolides inhibited MON metabolism, but the extent of inhibition observed with triacetyl-oleandomycin was higher than that produced by TIL, TUL, and GAM. Molecular docking analyses indicated that triacetyl-oleandomycin and MON exhibited the highest binding affinities for the active site of CYP3A isozymes, compared with TIL, TUL, and GAM. The agreement between enzymatic data and in silico predictions indicates that TIL, TUL, and GAM are weaker inhibitors of CYP3A-mediated MON metabolism. The modest reduction in MON hepatic metabolism caused by these macrolides-commonly used in cattle feedlots-suggests a low likelihood of clinically relevant drug-drug interactions under typical dosing conditions.